-
Recent Posts
- Will ProText Mobility, Inc. (OTCQB: TXTM) Find a Way to Monetize Applications for Mobile Communications Market?
- Can Tranzbyte Corporation (PINKSHEETS: ERBB) Overcome Concerns Surrounding Marijuana Business?
- SoundBite Communications (NASDAQ: SDBT) Surges Following Acquisition Agreement
- Is Regenerative Medicine Realistic for YaFarm Technologies (PINKSHEETS: YFRM)?
- Can Raptor Pharmaceutical Corp. (NASDAQ: RPTP) Turn FDA Approval into Big Payday Down the Road?
Categories
OTC Equity Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
Tags
aapl advertising alternative energy amex apple basic materials biopharmaceutical biotechnology cancer capital goods cloud computing copper drilling energy energy stocks exploration facebook fda fda approval gas gold gold mining google healthcare stocks investors ipad iphone mining NASDAQ natural gas nyse oil oil and gas otcbb penny stock penny stocks petroleum pharmaceutical pinksheets Pink Sheets s silver sprint stocks tradingSite
OTCEquity is a premier site for updated news and financial information regarding penny stocks and small cap companies. We offer a free newsletter, articles about penny stock trading, otc bulletin board analytical data and original news stories about the penny stock companies you are interested in.
Registration to our newsletter is FREE, Join today by entering your email below!
Tag Archives: sanofi
Exelixis, Inc. (NASDAQ: EXEL) Remains a Big Risk Big Reward Biotech with Everything Riding on Cancer Drug Cabozantinib
It’s possible that the climb back north may have started for Exelixis, Inc. (NASDAQ: EXEL) as the biotechnology company is now in recovery mode following yesterday’s poor performance. On Wednesday shares of EXEL sank as low as 4.27 as investors … Continue reading
Posted in Articles, NASDAQ
Tagged biotech, cabozantinib, cancer, clinical trial, exel, exelixis, fda, investors, lung, mcrpc, sanofi
Leave a comment
Can Investors Capitalize Off Misfortunes of Dendreon Corp. (NASDAQ: DNDN)?
One year ago shares of Dendreon Corp. (NASDAQ: DNDN) were trading at a 52-week high of 37.19 and the darling of the biotechnology industry with a prostate cancer drug on the market that was almost certainly going to bring in … Continue reading
Posted in Articles, NASDAQ
Tagged biotechnology, cancer drug, dendreon corp, dndn, investors, prostate cancer, provenge, sanofi
Leave a comment


